PMID- 30991394
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20210301
IS  - 1421-9867 (Electronic)
IS  - 0012-2823 (Linking)
VI  - 101
IP  - 3
DP  - 2020
TI  - A Potassium-Competitive Acid Blocker-Based Regimen as Second-Line Therapy 
      Improves Helicobacter pylori Eradication.
PG  - 332-338
LID - 10.1159/000499857 [doi]
AB  - BACKGROUND/AIMS: Although a potassium-competitive acid blocker (PCAB)-based 
      regimen improves the rate of successful Helicobacter pylori first-line 
      eradication, the efficacy of a PCAB-based regimen as second-line therapy is 
      unclear. The aim of this study is to compare the success of second-line 
      eradication of H. pylori using PCAB and proton pump inhibitor (PPI)-based 
      regimens. METHODS: From 2014 to 2017, 624 patients who underwent second-line H. 
      pylori eradication were enrolled. A standard triple regimen for second-line 
      H. pylori eradication includes metronidazole 250 mg, amoxicillin 750 mg, and PPI 
      or PCAB twice daily for 7 days. The success of eradication was compared using 
      intention-to-treat, per-protocol, and propensity-score matching analysis. 
      RESULTS: All patients completed the 7-day course of therapy. Patients using a 
      PCAB-based regimen had a higher rate of eradication than those using a PPI-based 
      regimen in both intention-to-treat (90% [298/330] vs. 85% [250/294], p = 0.045) 
      and per-protocol analyses (96% [298/309] vs. 91% [250/274], p = 0.008). Adverse 
      events occurred in 4 patients. Propensity score matching analysis acquired 274 
      matched pairs. Patients using a PCAB-based regimen had a higher rate of 
      eradication than those using a PPI-based regimen (96% [264/274] vs. 91% 
      [250/274], p = 0.013). CONCLUSIONS: PCAB-based second-line H. pylori eradication 
      is significantly better than PPI-based therapy.
CI  - (c) 2019 S. Karger AG, Basel.
FAU - Nabeta, Haruaki
AU  - Nabeta H
AD  - Department of Gastroenterology, Utsunomiya Memorial Hospital, Utsunomiya, Japan.
FAU - Shinozaki, Satoshi
AU  - Shinozaki S
AD  - Shinozaki Medical Clinic, Utsunomiya, Japan, shinozaki-s@aqua.ocn.ne.jp.
AD  - Division of Gastroenterology, Department of Medicine, Jichi Medical University, 
      Shimotsuke, Japan, shinozaki-s@aqua.ocn.ne.jp.
FAU - Abe, Yasuhiro
AU  - Abe Y
AD  - Department of Gastroenterology, Utsunomiya Memorial Hospital, Utsunomiya, Japan.
FAU - Koyanagi, Ryota
AU  - Koyanagi R
AD  - Department of Gastroenterology, Utsunomiya Memorial Hospital, Utsunomiya, Japan.
FAU - Nakamichi, Taro
AU  - Nakamichi T
AD  - Department of Gastroenterology, Utsunomiya Memorial Hospital, Utsunomiya, Japan.
FAU - Kobayashi, Yasutoshi
AU  - Kobayashi Y
AD  - Division of Gastroenterology, Department of Medicine, Jichi Medical University, 
      Shimotsuke, Japan.
FAU - Lefor, Alan Kawarai
AU  - Lefor AK
AD  - Department of Surgery, Jichi Medical University, Shimotsuke, Japan.
FAU - Hirashima, Hayato
AU  - Hirashima H
AD  - Department of Gastroenterology, Utsunomiya Memorial Hospital, Utsunomiya, Japan.
LA  - eng
PT  - Journal Article
DEP - 20190416
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - 0 (Antacids)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 140QMO216E (Metronidazole)
RN  - 804826J2HU (Amoxicillin)
RN  - RWP5GA015D (Potassium)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Amoxicillin/administration & dosage/adverse effects
MH  - Antacids/*administration & dosage/adverse effects
MH  - Anti-Bacterial Agents/*administration & dosage/adverse effects
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination/adverse effects/methods
MH  - Endoscopy, Digestive System
MH  - Female
MH  - Helicobacter Infections/diagnosis/*drug therapy/microbiology
MH  - Helicobacter pylori/*isolation & purification
MH  - Humans
MH  - Male
MH  - Metronidazole/administration & dosage/adverse effects
MH  - Middle Aged
MH  - Potassium/metabolism
MH  - Propensity Score
MH  - Proton Pump Inhibitors/*administration & dosage/adverse effects
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antibiotics
OT  - Gastric acid
OT  - Helicobacter pylori
OT  - Proton pump inhibitors
OT  - Treatment outcome
EDAT- 2019/04/17 06:00
MHDA- 2021/03/02 06:00
CRDT- 2019/04/17 06:00
PHST- 2018/10/22 00:00 [received]
PHST- 2019/03/25 00:00 [accepted]
PHST- 2019/04/17 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
PHST- 2019/04/17 06:00 [entrez]
AID - 000499857 [pii]
AID - 10.1159/000499857 [doi]
PST - ppublish
SO  - Digestion. 2020;101(3):332-338. doi: 10.1159/000499857. Epub 2019 Apr 16.